Predictive efficacy of serum soluble PD-L1 on patients with metastatic renal cell carcinoma treated with Nivolumab

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2023 Results evaluating sPD-L1 in mRCC patients treated with nivolumab and investigating the association between sPD-L1 and treatment response, presented at the 118th Annual Meeting of the American Urological Association
28 Jan 2023 Results assessing soluble PD-L1 levels in patients with mRCC treated with nivolumab and investigated its association with treatment response, published in the Anticancer Research.
07 Oct 2020 Planned End Date changed from 30 Apr 2024 to 30 Apr 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com